Reports Q3 revenue $2.8B, consensus $2.77B. “In the third quarter we delivered both sales and profit ahead of our expectations,” said IFF CEO Frank Clyburn. “Our volume performance improved sequentially across the majority of our business, and we continued to benefit from our pricing actions and productivity initiatives. Our emphasis to drive working capital improvement yielded strong free cash flow generation, led by a significant reduction in inventory over the course of the year. As we look ahead, we remain committed to delivering our previously announced full year 2023 sales guidance range, and now believe that we can achieve full year 2023 adjusted operating EBITDA at the mid to high-end of our previously announced guidance range.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IFF:
- Early notable gainers among liquid option names on November 7th
- International Flavors options imply 6.7% move in share price post-earnings
- IFF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- IFF to divest Cosmetic Ingredients business unit for $810M
- IFF weighs potential $3.5B sale of pharma solutions unit, Bloomberg says